Andrew Catchpole, Chief Scientific Officer of hVIVO , joins Martin Luke of Vox Markets to discuss hVIVO’s newly signed £6 million influenza human challenge trial contract. Andrew explains how the study will evaluate a prophylactic antiviral treatment using hVIVO’s specialist influenza challenge model, highlighting the speed and efficiency advantages of human challenge trials, the growing focus on antiviral therapies, and why hVIVO continues to attract global clients.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
